bpc-157 legal status us 2025 is in the Regulatory Alert: of Compounding and Clinical Practice – Holt Law FDA panel votes to place – Is BPC‑157 Legal? WADA, FDA

Loading phase protocol (acute injury or initial treatment): Dose: 500 mcg to 1 mg per injection Frequency: Once daily Duration: 7 to 10 days Injection site: Subcutaneous, ideally near the area of concern Timing: Morning or evening, consistency matters more than specific time Maintenance phase protocol: Dose: 500 mcg to 1 mg per injection Frequency: 2 to 3 times per week Duration: 4 to 8 weeks total protocol length Cycle recommendation: 2 months on, 2 months off Unlike traditional BPC-157 acetate, which is often administered twice daily due to its shorter half-life, the enhanced stability of the arginate form typically allows for once-daily dosing during the loading phase

It can be administered by IM or IV routes, thus it becomes a preferred choice in numerous clinics and hospitals

The decision has sparked debate between expanding patient access and ensuring medicines meet established standards for safety and efficacy

AOD-9604 acts on adipocyte lipolysis pathways through beta-3 adrenergic receptor signalling, with effects measured at the fat cell level